Pharma Stock Pops on Wells Fargo Upgrade

Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90. The firm cited business development and pipeline progress, no longer seeing a "major cliff" from the loss of Keytruda (a cancer medication) exclusivity. Today's pop has MRK trading at its highest levels since January, breaking into positive territory for 2025. The stock has added roughly 18% in November, and now sits ...